Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Might Be Associated with Lung Adenocarcinoma Risk: a Nationwide Population-based Nested Case-control Study

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2020 Nov 16

PMID 33194058

Citations 6

Authors

Han-Lin Hsu

Chih-Hsin Lee

Chien-Hsin Chen

Jun-Fu Zhan

Szu-Yuan Wu

Affiliations

Soon will be listed here.

Abstract

Objectives: To analyze the association of the use of different doses of angiotensin II receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) independently with lung cancer risk and to evaluate the lung cancer type that may be related to ARB or ACEI use.

Patients And Methods: A nationwide population-based nested case-control study was conducted using Taiwan National Health Insurance Research Database linked to the Taiwan Cancer Registry database between January 1, 2000, and December 31, 2016. The cumulative defined daily dose (DDD) was estimated. We divided all users of ACEI or ARB into three categories based on the DDD of ACEI or ARB: low dose, middle dose, and high dose.

Results: We identified 16,091 patients with newly diagnosed lung cancer, and 80,455 controls with hypertension were selected. Univariate and multivariate conditional logistic regressions showed that the independent risk factor for lung cancer was high-dose (≥ 1095 DDD) ARB use (adjusted odds ratio [OR]: 1.069, 95% confidence interval [CI]: 1.02-1.12, = 0.003). An increase in lung adenocarcinoma (ADC) risk was associated with middle-dose (adjusted OR: 1.073, 95% CI: 1.01-1.14, = 0.025) to high-dose (adjusted OR: 1.106, 95% CI: 1.05-1.17, < 0.001) ARB use and high-dose ACEI use (adjusted OR: 1.095, 95% CI: 1.01-1.19, = 0.033). No association was observed between different ARB or ACEI dose levels and the risk of lung squamous cell carcinoma and small-cell lung carcinoma.

Conclusions: Our results suggest that the use of both ACEI and ARB at a high cumulative dose is associated with the risk of lung ADC.

Citing Articles

Association of chronic obstructive pulmonary disease with risk of lung cancer in individuals aged 40 years and older: A cross-sectional study based on NHANES 2013-2018.

Chen H, Hu X, Zhou J, He C, Wang K, Yi Q PLoS One. 2024; 19(10):e0311537.

PMID: 39441785 PMC: 11498685. DOI: 10.1371/journal.pone.0311537.

Integrating Expression Data-Based Deep Neural Network Models with Biological Networks to Identify Regulatory Modules for Lung Adenocarcinoma.

Fu L, Luo K, Lv J, Wang X, Qin S, Zhang Z Biology (Basel). 2022; 11(9).

PMID: 36138770 PMC: 9495551. DOI: 10.3390/biology11091291.

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer.

Wang Y, Wang Y, Han X, Sun J, Li C, Adhikari B Front Cardiovasc Med. 2022; 9:727487.

PMID: 35369296 PMC: 8968416. DOI: 10.3389/fcvm.2022.727487.

Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals.

Wang C, Huang C, Nguyen P, Lin M, Yeh C, Islam M Cancers (Basel). 2022; 14(5).

PMID: 35267516 PMC: 8909564. DOI: 10.3390/cancers14051211.

Insufficient pain control for patients with cancer and dementia during terminal cancer stages.

Hsu W, Hsieh J, Wang Y, Hsieh C, Lin H, Wu S Am J Transl Res. 2021; 13(11):13034-13042.

PMID: 34956521 PMC: 8661160.

References

Bangalore S, Kumar S, Kjeldsen S, Makani H, Grossman E, Wetterslev J . Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2010; 12(1):65-82. DOI: 10.1016/S1470-2045(10)70260-6. View

Liaw K, Chen C . Mortality attributable to cigarette smoking in Taiwan: a 12-year follow-up study. Tob Control. 1998; 7(2):141-8. PMC: 1759691. DOI: 10.1136/tc.7.2.141. View

Rosenthal T, Gavras I . Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009; 23(10):623-35. DOI: 10.1038/jhh.2009.21. View

Subramanian J, Govindan R . Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25(5):561-70. DOI: 10.1200/JCO.2006.06.8015. View

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

George A, Thomas W, Hannan R . The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010; 10(11):745-59. DOI: 10.1038/nrc2945. View

Nakazawa K, Kurishima K, Tamura T, Ishikawa H, Satoh H, Hizawa N . Survival difference in NSCLC and SCLC patients with diabetes mellitus according to the first-line therapy. Med Oncol. 2013; 30(1):367. DOI: 10.1007/s12032-012-0367-9. View

Lin Y, Hsieh M, Chang C, Chow J, Yuan K, Wu A . Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study. Radiother Oncol. 2018; 129(2):326-332. DOI: 10.1016/j.radonc.2018.07.012. View

Lin W, Ding Y, Hsu H, Chang J, Yuan K, Wu A . Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma. Cancer. 2017; 123(20):3904-3915. DOI: 10.1002/cncr.30823. View

10.

Neal J . Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist. 2010; 15(1):3-5. PMC: 3227884. DOI: 10.1634/theoncologist.2009-0306. View

11.

Sun S, Schiller J, Gazdar A . Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007; 7(10):778-90. DOI: 10.1038/nrc2190. View

12.

Chen T, Lin K, Yuan K, Chang C, Chow J, Wu S . Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study. Radiother Oncol. 2017; 129(1):23-29. DOI: 10.1016/j.radonc.2017.12.004. View

13.

Knoll G, Sahgal A, Nair R, Graham J, van Walraven C, Burns K . Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002; 112(2):110-4. DOI: 10.1016/s0002-9343(01)01068-3. View

14.

Yen Y, Chang J, Lin W, Chiou J, Chang Y, Chang C . Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques. Cancer. 2017; 123(11):2043-2053. DOI: 10.1002/cncr.30565. View

15.

Clere N, Corre I, Faure S, Guihot A, Vessieres E, Chalopin M . Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010; 127(10):2279-91. DOI: 10.1002/ijc.25234. View

16.

Chang C, Tsai H, Lin W, Chang J, Hsu H, Chow J . Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma. Radiother Oncol. 2017; 125(1):73-79. DOI: 10.1016/j.radonc.2017.08.025. View

17.

Yen Y, Hsu H, Chang J, Lin W, Chang Y, Chang C . Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment. Radiother Oncol. 2018; 129(1):52-60. DOI: 10.1016/j.radonc.2018.03.007. View

18.

Khuder S . Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001; 31(2-3):139-48. DOI: 10.1016/s0169-5002(00)00181-1. View

19.

Gallagher P, Cook K, Soto-Pantoja D, Menon J, Tallant E . Angiotensin peptides and lung cancer. Curr Cancer Drug Targets. 2011; 11(4):394-404. PMC: 3314267. DOI: 10.2174/156800911795538048. View

20.

Hicks B, Filion K, Yin H, Sakr L, Udell J, Azoulay L . Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018; 363:k4209. PMC: 6199558. DOI: 10.1136/bmj.k4209. View